OBIO logo

ORCHESTRA BIOMED HOLDINGS IN

OBIONASDAQ
🏆 #3145 by market capEarnings Nov 16US Equity
$5.99▲ $0.22 (+3.81%)
Pre-market · at close
🔔
Track OBIO
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 3.8%
7d▲ 9.7%
14d▲ 4.2%
30d▼ 1.6%
ytd▲ 44.7%
1y▲ 66.9%
🏦Market Cap
$360M
Small Cap
📈Revenue Growth (YoY)
986.1%
High Growth
📊Gross Margin
99.5%
High
💵FCF Margin
—
⚖️P/S Ratio
10.4x
Elevated
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$5.70 – $6.03
52-Week Range
$3.46 – $6.50
Volume (shares)
28,119
Avg Volume (shares)
—
Shares Outstanding
60.1M
Next Earnings
2026-11-16

Fundamentals Snapshot

Annual Revenue
$33M
Last Q Revenue
$88,000
P/E Ratio
—
P/S Ratio
10.4x
EPS (TTM)
$-1.00
Dividend Yield
—
Dilution (1yr)
+31.3%
OBIO logo

ORCHESTRA BIOMED HOLDINGS IN

OBIO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$33M▲ +1169.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
99.4%▲ +7.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$52M▼ −19.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$49M▼ −2.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
50.0M▲ +31.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2M▼ −$3M YoY
StockOtter · stockotter.space

About ORCHESTRA BIOMED HOLDINGS IN

Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
13 analysts
Strong Buy4
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.